• Publications
  • Influence
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Expand
  • 3,984
  • 157
  • Open Access
Gene expression correlates of clinical prostate cancer behavior.
Prostate tumors are among the most heterogeneous of cancers, both histologically and clinically. Microarray expression analysis was used to determine whether global biological differences underlieExpand
  • 2,307
  • 90
  • Open Access
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PURPOSE To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone. METHODS A committeeExpand
  • 1,680
  • 83
  • Open Access
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Prostate cancer is the second most common cancer in men worldwide and causes over 250,000 deaths each year. Overtreatment of indolent disease also results in significant morbidity. Common geneticExpand
  • 1,055
  • 72
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
The evolution of prostate cancer from an androgen-dependent state to one that is androgen-independent marks its lethal progression. The androgen receptor (AR) is essential in both, though itsExpand
  • 769
  • 59
  • Open Access
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Alternative Role for EZH2 Epigenetic regulators are implicated in cancer progression and proposed as therapeutic targets. Xu et al. (p. 1465; see the Perspective by Cavalli) report that EZH2Expand
  • 522
  • 45
The genomic complexity of primary human prostate cancer
Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here weExpand
  • 1,052
  • 44
  • Open Access
NCCN clinical practice guidelines in oncology: prostate cancer.
  • 756
  • 39
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxelExpand
  • 1,408
  • 37
  • Open Access
Early detection of prostate cancer: AUA Guideline.
PURPOSE The guideline purpose is to provide the urologist with a framework for the early detection of prostate cancer in asymptomatic average risk men. MATERIALS AND METHODS A systematic review wasExpand
  • 817
  • 33
  • Open Access